What Makes Vaccine Safety Research Credible?

Michael Osterholm, executive director of the Vaccine Integrity Project, said credible vaccine safety studies should set their methods before analyzing data, disclose the evidence they use and make their results reproducible. In a MedPage Today interview published October 19, 2026, he argued that those safeguards matter both for scientific reliability and for public trust, particularly when vaccine research is debated amid strong prior beliefs.

Osterholm said researchers should first explain what information gap a study is meant to address. He warned that research designed to confirm a prior position is different from research that approaches safety questions openly. In his view, the aim should be to gather more information, but through methods that can withstand scrutiny.

He called for decisions about the study population, comparison groups, outcomes and definitions of possible adverse reactions to be made before researchers examine results. Setting those choices in advance can reduce the risk of selectively reporting results that fit a preferred conclusion. The interview does not provide a protocol or findings from any specific study under discussion.

Osterholm also described making data and analysis tools available so other researchers and members of the public can replicate analyses or document differences. He said experts should review what a finding means and whether it warrants further study. A statistical association, he cautioned, does not by itself show that a vaccine caused an outcome; repeated analyses can produce chance associations.

Methods Shape Vaccine Safety Claims

Safety research can influence public decisions and confidence in vaccination, so a study’s process matters alongside its reported result. Prespecified methods and accessible data let outside reviewers test whether conclusions follow from the evidence and whether researchers changed definitions or analytical choices after seeing results.

Osterholm’s emphasis on timing also bears on public communication. If questions about study design are raised only after a result has been widely circulated, corrections may struggle to reach the same audience. He argued for monitoring proposed studies as they proceed and addressing concerns about definitions and methods while the work is underway.

His comments are a research standards argument, not evidence that a particular vaccine is safe or unsafe. They also do not independently assess the adequacy of existing monitoring. Readers should distinguish those broader points from the article’s report that Osterholm questioned the added value of certain proposed studies.

A Viewpoint on Proposed Studies

The material comes from MedPage Today’s October 19 installment of Off the ‘Page, a video series presenting perspectives on medical issues. The report identifies Osterholm as the executive director of the Vaccine Integrity Project and says he discussed standards for vaccine safety research in a recent viewpoint.

In the interview, Osterholm said he did not see benefits in the kinds of studies being proposed that were not already addressed by what he described as rigorous safety oversight of current vaccines. That is his assessment; the supplied report does not name the studies, identify their sponsors, compare monitoring systems, or provide evidence to verify that conclusion.

“The most important word that one can think about in talking about these kinds of studies is ‘transparency.’”

— Michael Osterholm, executive director of the Vaccine Integrity Project, in the MedPage Today interview

Which Studies Are at Issue?

The report does not specify which proposed studies Osterholm was referring to, how they would be designed, or what questions they would examine. It also does not identify the safety-monitoring systems he said already address those questions or provide comparative evidence about their scope.

No study results are presented in the supplied material, and the interview does not establish that any vaccine caused or did not cause a particular adverse event. It is also unclear what independent review arrangements, data-release plans or prespecified protocols apply to the studies under discussion. Those details would be needed to assess the research itself, rather than the standards Osterholm advocates.

Study Protocols and Reviews

The next useful developments would be publication of the studies’ protocols, definitions, data sources and analysis plans, followed by results that can be reviewed and reproduced. Independent expert scrutiny could help determine whether findings are robust, whether observed associations merit further research and what conclusions the evidence supports.

Osterholm urged ongoing scrutiny rather than waiting until findings are announced publicly. The supplied report gives no timetable for the proposed studies, no planned publication dates and no specific next review milestone. Until those details emerge, readers can evaluate the standards he describes but cannot judge the design or conclusions of the unnamed studies.

Key Questions

What did Osterholm say makes vaccine safety research credible?

He highlighted transparent methods, study decisions made before data analysis, reproducible results and review by experts who can assess what findings mean.

Did the report present new findings about vaccine safety?

No. It reports Osterholm’s views on research standards and proposed studies; it does not present new safety data or study results.

Does an association prove that a vaccine caused an outcome?

No. Osterholm said an association is not the same as cause and effect. A finding requires interpretation and may warrant further study, depending on the evidence and methods.

Which proposed studies was he discussing?

The MedPage Today report does not name the studies or give their protocols, sponsors or timelines. The specific research at issue remains unclear.

Source: rss